Liver represents the largest organ of the body performing a wide variety of roles that include converting food into energy, creating bile for proper digestion of food, and detoxifying alcohol and poisons from the blood. There are several kinds of liver diseases such as hepatitis A, hepatitis B, and hepatitis C; liver fibrosis, liver cancer; fatty liver disease and cirrhosis; hemochromatosis and Wilson disease.

The global liver diseases therapeutics market is estimated to account for US$ 12,851.3 Mn in terms of value in 2020 and is expected to reach US$ 24,921.3 Mn by the end of 2027.

Browse Summary of the Research Report- https://www.coherentmarketinsights.com/market-insight/liver-diseases-therapeutics-market-3809

Increasing prevalence of liver cancer is expected to propel growth of the global liver diseases therapeutics market over the forecast period. For instance, according to The American Cancer Society, in 2020, the U.S. is expected to record around 42,810 new cases and around 30,160 deaths due to primary liver cancer and intrahepatic bile duct cancer.

Moreover, increasing geriatric population is also expected to aid in growth of the market. For instance, according to the U.S. Census Bureau, the U.S. geriatric population is expected to reach 77 million by 2034.North America held dominant position in the global liver diseases therapeutics market in 2019, accounting for 38.6% share in terms of value, followed by Europe and Asia Pacific, respectively

Side effects and risks associated with liver diseases therapeutics is expected to hinder growth of the global liver diseases therapeutics market. The side effects associated with the use of liver therapeutics include, nausea, headache, fever loss of appetite, and drug-induced liver disease.Moreover, availability of alternate treatment procedures such as organ transplantation and liver resection is also expected to limit growth of the market.

R&D in immunotoxins is expected to offer lucrative growth opportunities for players in the global liver diseases therapeutics market. For instance, GPC3 is a cell surface heparan sulfate proteoglycan that is overexpressed in hepatocellular carcinoma. Anti-GPC3 immunotoxins can be effective in the treatment of human hepatocellular carcinoma.

Moreover, clinical trials for development of new therapies is also expected to aid in growth of the market. For instance, in March 2018, the U.S. FDA granted Orphan Drug Designation for Protagonist Therapeutics, Inc.’s PTG-300: a subcutaneous injectable in clinical development stage for the potential treatment of beta-thalassemia and liver fibrosis.The global liver diseases therapeutics market was valued at US$ 11,854.7 Mn in 2019 and is forecast to reach a value of US$ 24,921.3 Mn by 2027 at a CAGR of 9.7% between 2020 and 2027.

Major organizations are focused on providing treatment guidelines for liver diseases during the COVID-19 pandemic. For instance, in March 2020, The American Association for the Study of Liver Disease released a clinical insight document for clinicians and frontline healthcare providers engaged in the treatment of patients with liver disease during the COVID-19 pandemic.

Increasing consumption of alcohol is expected to aid in growth of the market. For instance, according to the 2018 National Survey on Drug Use and Health (NSDUH), 86.3 percent of people ages 18 or older reported that they drank alcohol at some point in their lifetime.

Major players operating in the global liver diseases therapeutics market include, Astellas Pharma Inc., Bristol-Myers Squibb, Gilead Sciences, Glaxosmithkline Plc, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A, Pfizer Inc., Takeda Pharmaceutical, Valeant Pharmaceuticals, Watson Pharmaceuticals, Inc., Theratechnologies Inc., Alnylam Pharmaceuticals, Inc., Protagonist Therapeutics, Inc., Dicerna Pharmaceuticals, Inc., Endo International, Provectus Biopharmaceuticals Inc., and MAX BioPharma, Inc.

Major players in the market are focused on adopting collaboration strategies to expand their product portfolio. For instance, in April 2020, Alnylam Pharmaceuticals, Inc. collaborated with Dicerna Pharmaceuticals, Inc. for the development and commercialization of investigational RNAi therapeutics for the treatment of alpha-1 antitrypsin deficiency-associated liver disease.

Major players in the market are also focused on approval and launch of generic therapies for the treatment of liver diseases. For instance, in September 2019, Endo International received the U.S. FDA approval for its generic version of Syprine, a drug used for the treatment of Wilson's disease.


Request A Sample Copy - https://www.coherentmarketinsights.com/insight/request-sample/3809

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]
*****************************************************************************